Ultime notizie per Emmaus Life Sciences (OTC:EMMA) Azioni

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

EMMAUS LIFE SCIENCES INC by Emmaus Life Sciences, Inc.

Emmaus Life Sciences Inc

<a href="https://www.globenewswire.com/Tracker?data=Yw-TWCZN9-grHtHI6xQ1MISsc5A_cnAd6iOP9HS2de_E9bO6kmRPpQ7-DdhCIp1XU_MLP8EPDO09LPQydV9zw0TvgUE4ojq7agmELTp5-SL1MHzrzstoyetmyPIknCr7">Plymouth Industrial REIT, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) (the "Company" or "Plymouth") provided an activity update for the first quarter of 2025. The Company also announced details for its first quarter earnings conference call and webcast to be held on May 2, 2025.
Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, "Our strong leasing activity in the first quarter underscores the continued demand for well-located, functional industrial space across our markets. Additionally, our acquisition activity remains disciplined and strategic, as we continue to expand our footprint in key logistics hubs with assets that we expect will offer immediate cash flow and long-term value creation."
Leasing Activity Leases commencing during the first quarter ended March 31, 2025, all of which have terms of at least six months, totaled an aggregate of 2,437,267 square feet. These leases included 1,540,756 square feet of renewal leases and 896,511 square feet of new leases. Excluding the effect of the previously announced executed two-year lease at our 769,500-square-foot Class A building in St. Louis (the "St. Louis lease") that commenced on January 15, 2025, rental rates under these leases reflect a 16.2% increase on a cash basis with renewal leases reflecting a 15.0% increase on a cash basis and new leases reflecting a 22.1% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 9.6% on a cash basis and new leases would have increased 0.9% on a cash basis.
Same store occupancy at March 31, 2025, was 94.7%.&nbsp;&nbsp; Total portfolio occupancy at March 31, 2025, was 94.3% which reflects changes from last quarter including a 210-basis-point positive impact from the St. Louis lease, a 45-basis-point positive impact from leasing in in Cleveland, a 15-basis-point positive impact from acquisitions in Cincinnati and Atlanta markets and a net 70-basis-point negative impact from other leasing activity in the quarter.
Executed leases that will commence during 2025, all of which have terms of at least six months, totaled an aggregate of 4,652,684 square feet. These leases, which represent 56.3% of total 2025 expirations, include 3,731,230 square feet of renewal leases (30.0% of these renewal leases were associated with contractual renewals; there only remains a potential of 120,641 square feet of contractual renewals left in 2025) and 921,454 square feet of new leases, of which 740,487 square feet was vacant at the start of 2025. Excluding the effect of the St. Louis lease, rental rates under these leases reflect a 21.8% increase on a cash basis with renewal leases reflecting a 14.7% increase in rental rates on a cash basis and new leases reflecting a 15.3% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 12.1% on a cash basis and new leases would have increased 1.7% on a cash basis.
Acquisition Activity During the first quarter of 2025, Plymouth closed on the acquisition of six industrial buildings totaling 801,161 square feet for a total of $65.1 million and a weighted average initial estimated net operating income ("NOI") yield of 6.8%. Taken together, these 100% leased properties feature a weighted average remaining lease term of 4.4 years. The first quarter activity comprises the following:
<ul>
<li>263,000 square foot industrial building in Cincinnati, Ohio for $23.3 million and an initial estimated NOI yield of 6.7%.</li>
<li>Madison International's 98% joint venture interest in a 297,583 square-foot warehouse facility in Atlanta, Georgia with 100% occupancy for $23.9 million and an initial estimated NOI yield of 6.8%.</li>
<li>The second tranche of the previously announced Cincinnati small bay industrial portfolio consisting of four buildings totaling 240,578 square feet for $17.9 million and representing an estimated NOI yield of 7.0%. &nbsp;</li>
</ul>
Market Portrait Series&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We issued our second Market Portrait with Avison Young highlighting the Memphis industrial market - America's Distribution Center. The Portrait can be found on our corporate website under <a href="https://www.globenewswire.com/Tracker?data=WQ1381YMiTO9gZWqd6tj-ZMNvBYqYE254AygMFMeZN-NmRG6lwAoC9wkc5l3i0enOvFVcIPhVSa3mZAMfWPTGJ-SH_EgQtJUEfOrT84QgHfbXvBabSov5t2KEBwWZyhP5rDZEB_m8nKSLeJgBwdHyw==">Portfolio / Portfolio Map / Memphis</a>.
Known as "America's Distribution Center," Memphis' freight transportation infrastructure connects companies to nearly every major national and international market. Home to the FedEx World SuperHub, Memphis offers local companies an advantage as the cutoff time to drop off packages for next day delivery is later than counterparts in other U.S. cities. The market is served by five Class 1 railroads and is a key market where the eastern railroads CSX and NS can interconnect with western railroads BNSF and UP. In addition, Canadian National offers a key connection from the Gulf Coast to Canada via Memphis. The Memphis region is serviced by six interstate highways, the most significant being I-55 connecting Chicago to New Orleans and I-40 connecting California to North Carolina.
As of December 31, 2024, Memphis was our largest wholly-owned single market position with 63 buildings across approximately 6.4 million square feet.

News

PLYM

Plymouth REIT Signs Over 2.4M Square Feet in Q1 Leases, Expands Footprint With $65M in New Property Deals, Boosts Occupancy in Key Logistics Hubs

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Biotech

Health Care

General

TNXP

Tonix Pharmaceuticals Presented Data And Analyses Of TNX-102 SL Treatment Effects On Fibromyalgia At The American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

BRKR

Bruker Launches 1.3 GHz High-Resolution Nuclear Magnetic Resonance System

Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and maintains $65 price target.

Price Target

Reiteration

Analyst Ratings

DKNG

Needham Reiterates Buy on DraftKings, Maintains $65 Price Target

Bruker Launches Fourier 80 Multinuclear Benchtop FT-NMR Spectrometer To Enable  X-Nucleus Observations And various 2D Experiments

ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA's strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.
"ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States," said Adam Grossman, President and Chief Executive Officer of ADMA. "The tariffs that have been implemented on foreign goods, services and manufacturing should have no impact on ADMA and its supply chain or production operations. The Company's vertically integrated supply chain is fully domiciled in the U.S., providing end-to-end domestic control over sourcing, manufacturing, and distribution. Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience and regulatory compliance, but also aligns with increasing federal and private sector preferences for U.S.-made products and services. By maintaining complete operational control within the U.S., ADMA is uniquely well-positioned to capitalize on national economic incentives and deliver reliable, secure, and high-quality offerings to its domestic customer base."

Government

Regulations

ADMA

ADMA Highlights US-Based Supply Chain as Key Advantage in Tariff Era

MRNA

Moderna Will Present Research Across Multiple Infectious Disease Areas, Including COVID-19, Influenza, Respiratory Syncytial Virus, Cytomegalovirus, Norovirus, And mpox, At The European Society Of Clinical Microbiology And Infectious Diseases

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

<ul>
<li>Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days.</li>
<li>Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist.</li>
<li>iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026.</li>
</ul>

IBIO

iBio's Non-GLP Non-human Primate Pharmacokinetics Study Suggests IBIO-600, Anti-myostatin Antibody Designed For Subcutaneous Administration, Could Provide A Significantly Extended Half-life In Humans And A Weight Loss Treatment Option While Preserving And Promoting Muscle Growth

Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>, TASE: GILT))), a worldwide leader in satellite networking technology, solutions and services, announced today that Gilat Defense was awarded a contract to provide ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed worldwide in support of U.S. Department of Defense (DoD) customers. The contract includes a base program with options to extend up to five years, totaling up to $23 million.
Under the agreement, Gilat Defense will deliver critical program management, field services, and technical support, ensuring operational readiness and continued reliability of these vital communication assets.

GILT

Gilat Wins $23M Deal to Support Satellite Terminals for US Defense Department

<ul>
<li>Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks.</li>
<li>19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks.</li>
<li>20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks.</li>
<li>Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025.</li>
</ul>

RYTM

Rhythm Pharmaceuticals' Phase 3 TRANSCEND Trial Of Setmelanotide For Acquired Hypothalamic Obesity, Met Its Primary Endpoint With Statistically Significant And Highly Clinically Meaningful Reduction In Body Mass Index In Adult And Pediatric Patients Versus Placebo

United Homes Posts 22.9% Decrease In Q1 Net New Orders

Republic Airways Holdings Inc. and Mesa Air Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) today announced that they have entered into a definitive agreement to merge and create a leading publicly-traded regional airline company in an all-stock transaction. Upon closing, the combined company will be renamed Republic Airways Holdings Inc. and is expected to remain NASDAQ-listed under the new ticker symbol "RJET".

MESA

Republic Airways and Mesa Air Merge in All-Stock Deal to Create New Nasdaq-Listed Airline

<ul>
<li>While the Company's presence in the U.S. opioids market is very small, the Company has agreed to this settlement to provide closure on these matters. This settlement is in no way an admission of wrongdoing or liability.</li>
<li>Under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues. The Company had already accrued an estimate in respect of a potential settlement, which is reflected in the Company's annual report on Form 10-K for the year ended December 31, 2024. &nbsp;</li>
<li>The Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids. For example, the Company manufactures a generic injectable version of the life-saving overdose reversal drug, naloxone, as well as a generic buprenorphine/naloxone product used for the treatment of opioid addiction. The Company is also developing a novel delivery for meloxicam, a non-opioid pain medication. &nbsp;</li>
</ul>

Legal

VTRS

Viatris Reached A Nationwide Settlement Framework To Resolve Opioid-related Claims By States, Local Governments, And Tribes Against The Company And Certain Of Its Subsidiaries, The Company Would Pay Up To A Maximum Of $335M

HC Wainwright &amp; Co. analyst Scott Buck maintains Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) with a Buy and lowers the price target from $16 to $12.

KSCP

HC Wainwright & Co. Maintains Buy on Knightscope, Lowers Price Target to $12

Earnings

Earnings Beats

PHVS

Pharvaris Q4 2024 GAAP EPS €(0.64) Beats €(0.71) Estimate, Cash Balance Of €281M

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) with a Buy and maintains $2.5 price target.

DGXX

HC Wainwright & Co. Reiterates Buy on Digi Power X, Maintains $2.5 Price Target

A report&nbsp;indicated that new tariff policies could lead to increased costs for American households, while President Donald Trump continues to advocate tariffs as a solution to U.S. trade deficits
What Happened: A Yale budget lab report suggests that U.S. households will face increased costs due to these tariffs. Families are projected to face an average additional cost of $3,800 this year as a result of the overall 2025 tariffs, which are expected to increase price levels by 2.3% in the short term. 
Meanwhile, the April 2 &#8216;Liberation Day&#8217; tariffs alone are likely to increase the average cost of $2,100 per household in 2025. The report also stated that households at the lowest end of the income distribution face annual losses of $1,700.
Both the April 2 tariffs and the combined 2025 tariffs impact the clothing and textile sector, causing apparel prices to increase by 17% under the full set of tariffs, stated the Yale report.
However, Trump took to his Truth Social and pushed for tariffs as a means to address trade deficits with nations such as China and the European Union. He argued that the tariffs already in place have generated substantial revenue—tens of billions of dollars—for the country, and criticized the Biden administration for&nbsp;trade surpluses favoring foreign nations. He also promised a swift reversal of this trend.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="612" height="288" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07055131/image-53.png" alt="" class="wp-image-859562" style="width:508px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07055131/image-53.png 612w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07055131/image-53-300x141.png 300w" sizes="(max-width: 612px) 100vw, 612px" /></figure>
SEE ALSO:&nbsp;<a href="https://benzinga.com/general/market-summary/25/04/44660779/sp-500-dow-jones-on-course-to-mimic-rare-consecutive-losses-not-seen-since-the-great-depre" target="_blank" rel="noreferrer noopener">S&amp;P 500, Dow Jones On Course To Mimic Rare Consecutive Losses Not Seen Since The Great Depression: What&#8217;s Driving the Fear?</a>
Why It Matters: The proposed tariffs have sparked concerns about potential inflation. Federal Reserve Chair Jerome Powell hinted at this possibility in a&nbsp;<a href="https://www.benzinga.com/government/regulations/25/04/44648681/powell-cites-tariff-driven-inflation-risks-shrugs-off-trumps-call-for-perfect-time-to-cut-rates">speech</a>&nbsp;earlier this month. He indicated that higher tariffs could complicate the path toward price stability, raising the risk of both slower growth and rising inflation.
Furthermore, billionaire entrepreneur Mark Cuban has warned that even American-made goods will see price hikes due to tariffs. In a <a href="https://www.benzinga.com/news/25/04/44656363/stock-up-now-says-mark-cuban-he-warns-that-even-american-made-goods-will-see-price-hikes-soon">Bluesky post</a>, Cuban urged Americans to stock up on essentials before prices rise further. He suggested that even if goods are made in the U.S., retailers will increase the price and blame it on tariffs.
Global markets have been on a rollercoaster ride due to President Donald <a href="https://in.benzinga.com/media/25/04/44657800/trumps-tariffs-stir-global-markets-wall-street-loses-2-trillion-and-more-this-week-in-economics" target="_blank" rel="noreferrer noopener">Trump&#8217;</a><a href="https://in.benzinga.com/media/25/04/44657800/trumps-tariffs-stir-global-markets-wall-street-loses-2-trillion-and-more-this-week-in-economics" target="_blank" rel="noreferrer noopener">s new trade tariffs</a>. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which mirror the S&amp;P 500 and Nasdaq-100 indexes, respectively, slipped in premarket trading Monday. SPY fell 4.01% to $485.03, while QQQ dropped 4.26% to $404.65, according to <a href="http://pro.benzinga.com">Benzinga Pro data.</a>
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/44661347/xrp-futures-traders-bet-on-cryptos-price-increase-despite-a-20-fallheres-what-analysts-predict" target="_blank" rel="noreferrer noopener">XRP Futures Traders Bullish On Coin&#8217;s Price Increase Despite A 20% Fall — Analyst Terms Decline As &#8216;Small Speed Bump&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Economics

Markets

Trump Tariffs Could Cost American Families $3,800 More Per Year — But President Says They're 'Bringing Tens Of Billions Of Dollars Into The US'

The ongoing U.S. trade war has put tech giants like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Facebook-parent Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google at the heart of negotiations, with the EU preparing retaliatory measures and the U.K. offering tax relief to secure lower tariffs.
What Happened: The U.K. government made a move to pacify President Donald Trump's tariffs by offering significant tax relief to U.S. tech giants. U.K. Prime Minister Keir Starmer proposed reducing the digital services tax (DST) for major U.S. tech firms in exchange for lower tariffs, <a href="https://www.theguardian.com/us-news/2025/apr/01/starmer-offered-big-us-tech-firms-tax-cuts-in-return-for-lower-trump-tariffs">reported</a> The Guardian.
The UK government is hoping this tax concession will help secure a carve-out from Trump's tariffs, particularly targeting products like cars and tech. The proposal would apply to companies like Apple, Facebook, Google, Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and others, which are currently subject to the UK's DST.
See Also:&nbsp;<a href="https://www.benzinga.com/tech/25/04/44658417/warren-buffett-stands-tall-in-2025-as-elon-musk-jeff-bezos-and-mark-zuckerberg-bleed-billions-in-net-worth-oracle-of-omaha-emerges-as-lone-gainer-among-top-billionaires-amid-market-rout" target="_blank" rel="noreferrer noopener">Warren Buffett Stands Tall In 2025 As Elon Musk, Jeff Bezos And Mark Zuckerberg Bleed Billions In Net Worth: ‘Oracle Of Omaha' Emerges As Lone Gainer Among Top Billionaires Amid Market Rout</a>
At the same time, the EU is preparing to retaliate against the new U.S. tariffs, which have already impacted European exports, especially in the tech sector.
French Economy Minister Eric Lombard indicated that Europe might strengthen regulations on U.S. tech firms, especially regarding data usage, <a href="https://www.politico.eu/article/france-suggest-to-regulate-data-in-response-to-trump-tariffs/">reported</a> Politico.
There is also the possibility of imposing new taxes on digital services if the tariffs continue to escalate. In contrast, Ireland, where many U.S. tech firms have their European headquarters, has fiercely rejected these ideas, citing the potential impact on its economy.
Why It Matters: Two of the U.S.&#8217;s largest trading partners—China and the European Union, accounting for 8% and 13% of total trade volumes, respectively—have signaled intentions to retaliate.
China has already <a href="https://www.benzinga.com/news/25/04/44645172/china-retaliates-with-34-tariff-on-all-us-imports-urges-trump-to-immediately-cancel-the-tariffs-calls-for-negotiation">implemented 34% reciprocal tariffs</a> on all U.S. imports, while the European Union is expected to announce countermeasures later this week.
In addition, the tariffs have brought together regional competitors—China, Japan, and South Korea—who are now coordinating a collective response.
Over the weekend, senior White House officials reported <a href="https://in.benzinga.com/25/04/44660475/more-than-50-nations-ready-to-revisit-tariffs-says-white-house-advisor">that more than 50 countries</a> affected by the U.S.&#8217;s reciprocal tariffs have initiated contact to begin negotiations.
This development comes as U.S. stock futures continued to plunge over the weekend, with Dow, S&amp;P 500, and Nasdaq futures falling by 2.7%, 6%, and 5.7%, respectively. Additionally, the U.S. dollar saw its sharpest drop since November 2022, sliding 1.7% on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/04/44657800/trumps-tariffs-stir-global-markets-wall-street-loses-2-trillion-and-more-this-week-in-economics" target="_blank" rel="noreferrer noopener">Trump's Tariffs Stir Global Markets, Wall Street Loses $2 Trillion, And More: This Week In Economics</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

Media

AAPL

AMZN

GOOG

GOOGL

Apple, Facebook, And Google Become Bargaining Chips In US Trade War: EU Threatens Retaliation, UK Offers Tax Relief For Lower Tariffs

Barrick Gold Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>), the world's second-largest gold producer, might change its name. Management proposed rebranding as Barrick Mining Corporation to reflect its broader mining focus.
They also laid out an ambitious plan to grow their <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">gold equivalent production</a> by 30% by the end of this decade.
"We are proposing to change our name from Barrick Gold Corporation to Barrick Mining Corporation to reflect the company's changing production profile," the company <a target="_blank" href="https://www.barrick.com/English/news/news-details/2025/future-focused-barrick-sets-sights-on-30-percent-production-growth-by-2030/default.aspx" rel="noreferrer noopener">said</a> in a press release.
CEO Mark Bristow has long supported diversifying the company's portfolio with copper, and his desire has started to materialize just as the orange metal became one of the principal commodities for the green technology push.
Notable projects include the Reko Diq copper-gold project in Pakistan and the Lumwana Expansion in Zambia, which is on track to become one of the<a target="_blank" href="https://www.benzinga.com/25/02/43843615/barrick-nears-malian-resolution-completes-feasibility-studies-for-two-world-class-projects" rel="noreferrer noopener"> largest copper mines globally</a>. Bristow is convinced that copper is crucial for future growth and long-term value for shareholders.
Reflecting on the performance, Chairman John Thornton highlighted solid achievements, even in challenging market conditions.
"We've seen an improvement in our financial results, with net earnings soaring by 69% — the highest in a decade," he stated in the company's <a target="_blank" href="https://s25.q4cdn.com/322814910/files/doc_downloads/agm/2025/Barrick_2025_Information_Circular.pdf" rel="noreferrer noopener">2025 Information Circular</a>. "Operating cash flow increased by 20%, and free cash flow has doubled compared to 2023," he highlighted.
Thornton outlined a path to sustainable growth by developing projects organically and achieving operational excellence. Alongside Reko Diq and Lumwana, Barrick is ramping up operations at Pueblo Viejo, moving forward with prefeasibility work at Fourmile, and has restarted activities at Porgera. These efforts are expected to enhance the company's production and profitability well into the next decade.
Despite optimistic metal prices, mining stocks have lagged, and Barrick is no exception. Spot gold price is up about 15% year-to-date, while Barrick gained 10.64%.
"We see our equity as undervalued and repurchased $498 million in shares in 2024. We plan to continue buybacks whenever shares are trading below their intrinsic value," Thornton noted, pointing to the firm's industry-leading balance sheet, strong liquidity, and portfolio of Tier 1 assets as principal advantages that can deliver the touted 30% growth.
To strengthen management, Barrick also announced the nomination of two new directors: former Shell CEO Ben van Beurden and Metso President Pekka Vauramo. These appointments will enhance the board's global mining and energy expertise.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44651093/iron-ore-set-to-slide-further-as-trump-tariffs-china-slowdown-collide-goldman-says" target="_blank" rel="noreferrer noopener">Iron Ore Set To Slide Further As Trump Tariffs, China Slowdown Collide, Goldman Says</a></li>
</ul>
Photo via Shutterstock

Large Cap

Commodities

Management

GOLD

Barrick Gold Proposes Name Change, Targets 30% Production Growth By 2030

Small Cap

Press Releases

Emmaus Life Sciences Reports Delayed Filing of Annual Report

Emmaus Life Sciences Reports 2023 Financial Results

Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program

Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer

Emmaus Life Sciences Reports Quarterly Financial Results

Emmaus Life Sciences Reports Improved Quarterly Financial Results

Contracts

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia

EMMA

Emmaus Life Sciences

Comments

Emmaus Life Sciences

Notizie

Ultime notizie per Emmaus Life Sciences (OTC:EMMA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO